By the time she diagnosed with GM1 Gangliosidoses she is no more: Case Presentation

Samundy Kumbhakar, Arvind Kumar Singh


Beta-galactosidase-1 deficiency is rare lysosomal storage disorder which is also called as GLB1 deficiency or Landing disease. It is an autosomal recessive disorder whose age of onset is usually child hood.  Deficiency of beta – galatosidase enzyme due to mutations of GLB1 gene results in toxic accumulation of gangliosides in either body tissues or particularly in the central nervous system which ultimately ends up in neurovisceral, ophthalmological and dysmorphic features. The types of GM1 gangliosidosis is based on the age of onset; infantile form which is severe and rapidly progressive, a late infantile or juvenile form with onset usually from seventh month to 3 years of age accompanied with delayed motor and cognitive development and thirdly an adult or chronic form with late onset characterized by generalized dystonia. The severity of disease depends on the level of beta – galactosidase activity. Due to the wide spectrum of disease, the diagnosis may be difficult. Facial coarsening, hypertrophic gums, cherry -red macula, visceromegaly, dysostosis and psychomotor are some signs of storage disorders which may help to diagnose GM1 gangliosidosis. The confirmative diagnosis is biochemical assay of beta – galactosidase activity by molecular genetic testing. GLB1 molecular analysis can be done either by chorionic villus or amniotic cells as prenatal diagnosis. There is no specific treatment for GM1 gangliosidosis; treatment is symptomatic as well as supportive. Extremely poor prognosis found in severe infantile form.


Full Text:



National Tay-Sachs & Allied Diseases, October 2016; Accessed at:

Genetic home reference, 2018; Accessed at:

GM1 gangliosidosis. Genetics Home Reference. August 2013; Available at.

Stephen L Nelson, GM1 Gangliosidosis; Accessed at:

National Tay-Sachs & Allied Diseases Association (NTSAD), GM1 Gangliosidosis – 1.Oct 2016. Available at:

David H Tegay, GM1 Gangliosidosis Workshop, Dec 2014 Available at:

Lyon, GL; et al. (1996), Neurology of Hereditary Metabolic Diseases of Children (2 ed.), p. 53–55

Bley, Annette E.; Giannikopoulos, Ourania A.; Hayden, Doug; Kubilus, Kim; Tifft, Cynthia J.; Eichler, Florian S. (2011-11-01). "Natural History of Infantile GM2 Gangliosidosis". Pediatrics. 128 (5): e1233–e1241)

Morrone A, Bardelli T, Donati MA, et al. Beta- galactosidase gene mutations affecting the lysosomal enzyme and the elastin-binding protein in GM1-gangliosidosis patients with cardiac involvement. Hum Mutat. 2000. 15(4): 354-66.

Suzuki Y, Oshima A, Nanba E. B- galactosidase deficiency ( B- Galactosidosis): GM1 gangliosidosis and Morquio B disease. Scriver CR, Sly WS, Valle D, et al, eds. The metabolic and molecular Bases of Inherited Disease. 8th Ed. McGraw – Hill Professional; 2001.Vol 3: 3775-810.

Chamoles NA, Blanco MB, Gaggioli D. Fabry disease: enzymatic diagnosis in dried blood spots on filter paper [Letter]. Clin Chim Acta 2001; 308:195-196.

Tegay D. GM1 Gangliosidosis. Medscape. March 29, 2012; Available at:

Dr Anna CACIOTTI - Dr Maria Alice DONATI - Dr Amelia MORRONE, The portal for rare diseases and orphan drugs, may 2012; Accessed at:

Jalan RA et al, Spectrum of lysosomal storage disorders in Inida and Pakistan,Poster Presented at SSIEM conference in Lyon, France (1st – 4th Sept 2015) Poster #558

GM 123.Gangliosidosis Awareness and Research Fund, 2015. Available at:


  • There are currently no refbacks.